Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intra-Cellular Ther
(NQ:
ITCI
)
75.76
+2.15 (+2.92%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Intra-Cellular Ther
< Previous
1
2
3
4
5
Next >
8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
April 03, 2024
Via
Benzinga
Where Intra-Cellular Therapies Stands With Analysts
February 23, 2024
Via
Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
February 21, 2024
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
Via
InvestorPlace
Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies
January 18, 2024
Via
Benzinga
In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies
January 02, 2024
Via
Benzinga
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
Expert Ratings for Intra-Cellular Therapies
December 11, 2023
Via
Benzinga
Intra-Cellular Therapies's Earnings: A Preview
November 01, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About Intra-Cellular Therapies
August 22, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
December 14, 2023
Via
Benzinga
Are These Biotechs Ready To Launch?
December 09, 2023
Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and...
Via
Talk Markets
Analyst Expectations for Intra-Cellular Therapies's Future
August 03, 2023
Via
Benzinga
Intra-Cellular Therapies Better Positioned For Success: Analyst Anticipates Positive Phase 3 Depression Trial Data
July 06, 2023
Needham increased the price target for Intra-Cellular Therapies Inc (NASDAQ: ITCI) from $70 to $73, with a Buy rating, noting high expectations regarding major depressive disorder (MDD) readouts are...
Via
Benzinga
Needham Maintains Buy Rating for Intra-Cellular Therapies: Here's What You Need To Know
July 06, 2023
Via
Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
June 22, 2023
Via
Benzinga
Analyst Expectations for Intra-Cellular Therapies's Future
June 05, 2023
Via
Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
May 04, 2023
Via
Benzinga
A Preview Of Intra-Cellular Therapies's Earnings
May 03, 2023
Via
Benzinga
Analyst Ratings for Intra-Cellular Therapies
March 29, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
April 20, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
April 07, 2023
Via
Benzinga
Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday
March 29, 2023
Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $450 to $475. Keybanc analyst Josh Beck maintained an Overweight rating. Intuit shares fell 1.8% to close at $419.33 on Tuesday.
Via
Benzinga
Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features
March 28, 2023
Via
Benzinga
Analyst Ratings for Intra-Cellular Therapies
March 02, 2023
Via
Benzinga
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 28, 2023
Gainers
Via
Benzinga
Why Intra-Cellular Therapies Climbed Tuesday
March 28, 2023
The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.
Via
The Motley Fool
Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted
March 28, 2023
The company believes it may have the answer for patients with "mixed features."
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 28, 2023
Via
Benzinga
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
March 15, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...
Via
FinancialNewsMedia
Exposures
COVID-19
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.